MINERALYS THERAPEUTICS, INC. Stock-Based Compensation
MINERALYS THERAPEUTICS, INC. (MLYS) reported Stock-Based Compensation of $13.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $7.36M, a 61.54% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.55M, a 79.64% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.29M, a 68.63% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.84M, a 86.08% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $19.32M, a 70.47% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $11.34M, a 124.03% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $5.06M, a 1012.09% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $455.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $13.90M 10-Q · filed 2026-08-11 | $19.19M derived: sum of 3 quarters · filed 2026-08-11 | $25.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.55M 10-Q · filed 2026-05-06 | $11.83M derived: sum of 2 quarters · filed 2026-05-06 | $17.67M derived: sum of 3 quarters · filed 2026-05-06 | $22.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.13M derived: sum of 2 quarters · filed 2026-03-12 | $15.68M derived: sum of 3 quarters · filed 2026-08-11 | $19.32M 10-K · filed 2026-03-12 |
| 2025-09-30 | $5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $10.39M derived: sum of 2 quarters · filed 2026-08-11 | $14.04M 10-Q · filed 2025-11-10 | $17.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $8.20M 10-Q · filed 2026-08-11 | $11.33M derived: sum of 3 quarters · filed 2026-08-11 | $14.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.65M 10-Q · filed 2026-05-06 | $6.78M derived: sum of 2 quarters · filed 2026-05-06 | $9.92M derived: sum of 3 quarters · filed 2026-05-06 | $12.79M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.27M derived: sum of 2 quarters · filed 2026-03-12 | $9.14M derived: sum of 3 quarters · filed 2026-03-12 | $11.34M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $6.01M derived: sum of 2 quarters · filed 2025-11-10 | $8.20M 10-Q · filed 2025-11-10 | $9.66M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.06M 10-Q · filed 2025-08-12 | $6.52M derived: sum of 3 quarters · filed 2025-08-12 | $8.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.19M 10-Q · filed 2025-05-12 | $3.65M derived: sum of 2 quarters · filed 2025-05-12 | $5.23M derived: sum of 3 quarters · filed 2025-05-12 | $6.50M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $3.04M derived: sum of 2 quarters · filed 2025-02-12 | $4.31M derived: sum of 3 quarters · filed 2025-02-12 | $5.06M 10-K · filed 2025-02-12 |
| 2023-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.85M derived: sum of 2 quarters · filed 2024-11-12 | $3.60M 10-Q · filed 2024-11-12 | $3.82M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.02M 10-Q · filed 2024-08-13 | $2.24M derived: sum of 3 quarters · filed 2024-08-13 | $2.44M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $749.00K 10-Q · filed 2024-05-09 | $967.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.16M derived: sum of 3 quarters · filed 2024-05-09 | $1.19M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $410.00K derived: sum of 2 quarters · filed 2024-03-21 | $436.00K derived: sum of 3 quarters · filed 2024-03-21 | $455.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $218.00K derived: sum of 2 quarters · filed 2023-11-07 | $237.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $45.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $19.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |